Europe PCR for Respiratory Infection Diagnostics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type, Product Type, Infection Type, and End User

Europe PCR for Respiratory Infection Diagnostics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type, Product Type, Infection Type, and End User

  • August 2021 •
  • 248 pages •
  • Report ID: 6134303 •
  • Format: PDF
The Europe PCR for respiratory infection diagnostics market is expected to reach US$ 2,432.46 million by 2028 from US$ 1,241.01 million in 2021; it is estimated to grow at a CAGR of 10.1% from 2021 to 2028.

The growth of the market is attributed to some of the key driving factors, such as increasing burden of chronic respiratory diseases (CRDs) and increasing use of PCR testing for various respiratory infection diagnostics. However, availability of alternative assays is the major factor hindering the market growth.

Chronic respiratory diseases (CRDs) are among the leading causes of morbidity globally due to the heavy consumption of tobacco.For instance, according to the National Health Services, in England, nearly one in five people is affected by a respiratory disease, and respiratory diseases is the third leading cause of deaths.

The burden of CRDs is expected to increase in the future due to poor air quality, addiction to smoking, and rise in geriatric population is more prone to COPD and lung cancer.Moreover, programs initiated in the countries to improve treatment and support the people living with respiratory diseases are likely to increase the demand for PCR for the diagnosis of respiratory diseases.

This will lead to the market growth during the forecast period.PCR testing is the gold standard for detecting respiratory infectious diseases, including SARS-CoV-2.

Also, the growing developments in PCR are not limited to the COVID-19 testing. The continuous technological developments have allowed researchers to develop advanced PCR techniques at a reduced cost and limit their complexities. In addition, PCR testing is significantly used in institutions such as nursing homes, chronic care facilities, and hospitals for identifying influenza virus infection that causes respiratory outbreaks. Therefore, various companies are offering PCR kits that can detect the presence of pathogens that cause respiratory diseases. Apart from the increasing incidence of acute and chronic respiratory diseases, other factors such as environmental and climatic conditions, air pollution, and discoveries of novel bacteria, viruses, and pathogens are likely to serve as vital growth opportunities for PCR testing for respiratory infection diagnostics in the future.

The European economy is seriously hit due to the exponential growth of COVID-19 cases in the region.The rising occurrence rate of coronavirus results in increased stress on the region’s healthcare system, which is also rising the demand for diagnostic tests in its healthcare system, supporting the expansion of the sector in this region.

Several manufacturers are developing advanced PCR test kits and systems for the detection of COVID-19 virus.As the coronavirus increases, millions of people will need testing.

Thus, high throughput molecular testing is expected to play a central role in the future management of the COVID-19 pandemic. Therefore, the need for early detection of respiratory infection diseases is thought to be propelling the European PCR for respiratory infection diagnostics market growth during the forecast period.

Based on type, the Europe PCR for respiratory infection diagnostics market is segmented into real time PCR (qPCR), traditional PCR, reverse-transcriptase (RT-PCR), digital PCR, multiplex PCR, and others. The real-time PCR (qPCR) segment held the largest share of the market in 2021 and is anticipated to register the highest CAGR in the market during the forecast period.

Based on product type, the Europe PCR for respiratory infection diagnostics market is segmented into reagents and kits, instruments, and others. The reagents and kits segment held the largest share of the market in 2021 and is anticipated to register the highest CAGR in the market during the forecast period.

Based on infection type, the Europe PCR for respiratory infection diagnostics market is segmented into bacterial infection, viral infection, and fungal & other pathogens. In 2021, viral infections segment held the largest share of the market and is estimated to register the highest CAGR in the market during the forecast period.

Based on end user, the Europe PCR for respiratory infection diagnostics market is segmented into hospitals, physician clinics, clinical laboratories, academic and research institutions, biotech and pharma companies, and others. In 2020, clinical laboratories segment held the largest share of the market and is estimated to register the highest CAGR in the market during the forecast period.

A few of the primary and secondary sources associated with this report on the PCR for respiratory infection diagnostics market are European Lung Foundation (ELF), European Respiratory Society (ERS), European Medicines Agency (EMA), and European Centre for Disease Prevention and Control (ECDPC).
Loading...

We are very sorry, but an error occurred.
Please contact [email protected] if the problem remains.